The effectiveness of 4CMenB vaccine in preventing invasive meningococcal disease in children
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
|
Posted on February 17th, 2023
|
Neisseria meningitidis is the major bacterial cause behind invasive meningitis in children. The four-component protein-based meningococcal B vaccine (4CMenB) is sold by the pharmaceutical company GlaxoSmithKline under the brand name Bexsero and has been widely used worldwide. A recent study published in the New England Journal of Medicine had published their finding on the effectiveness of the 4CMenB vaccine on preventing infection in young children.
The case-control study was conducted in Spain and included 1530 children under the age of 5 years old. Neisseria meningitidis infection was confirmed with either a positive culture or PCR test in 306 of the children; 79.4% of them were infected with serogroup B bacteria. This case cohort was compared with a control group of 1224 children. The rate of vaccination was 11.4% in the case cohort, and 24.3% in the control counterpart. In children who were partially vaccinated - received only 1 of the 2 dose series - the vaccine effectiveness rate was 54%. The vaccine performance was significantly enhanced with the second dose. As in children who received both 4CMenB doses, the vaccine effectiveness rate in preventing invasive meningococcal disease caused by any serogroup is 76%. Specifically, the effectiveness in preventing meningococcal disease caused by Serogroup B bacteria was 71%, and 82% against non-serogroup-B bacteria.
The case-control study was conducted in Spain and included 1530 children under the age of 5 years old. Neisseria meningitidis infection was confirmed with either a positive culture or PCR test in 306 of the children; 79.4% of them were infected with serogroup B bacteria. This case cohort was compared with a control group of 1224 children. The rate of vaccination was 11.4% in the case cohort, and 24.3% in the control counterpart. In children who were partially vaccinated - received only 1 of the 2 dose series - the vaccine effectiveness rate was 54%. The vaccine performance was significantly enhanced with the second dose. As in children who received both 4CMenB doses, the vaccine effectiveness rate in preventing invasive meningococcal disease caused by any serogroup is 76%. Specifically, the effectiveness in preventing meningococcal disease caused by Serogroup B bacteria was 71%, and 82% against non-serogroup-B bacteria.